Thursday, July 14, 2022 @ 11:30 a.m. ET DURHAM, N.C., July 07, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that it will host a key opinion...
-- HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up to date, for treatment of peripheral arterial disease, arteriovenous access for hemodialysis, and trauma – -- Immediately-available HAV, if approved, would represent significant and innovative advancements for...
Industry leader brings deep expertise in international drug development, strategic leadership, and corporate partnering for biopharmaceutical companies DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing...
-- Successful first two HAV implantations in wounded Ukrainian citizens -- HAVs were provided under Humacyte’s initiative to assist Ukraine humanitarian medical effort -- Provides further real-world evidence of the potential of HAV treatment for trauma DURHAM, N.C., June 21, 2022 (GLOBE NEWSWIRE)...
-- Data indicate HAV does not stimulate increase in panel reactive antibodies, an adaptive immune response correlated with increased risk of implant failure -- -- Data presented today in IMPACT session at American Transplant Congress (ATC) 2022 -- DURHAM, N.C., June 08, 2022 (GLOBE NEWSWIRE) --...
DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Dale Sander, Chief Financial Officer, and Heather Prichard, Ph.D.,...
-- Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries -- -- Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer -- -- Multiple scientific meeting presentations and...
-- First shipment of HAVs to six Ukrainian hospitals made today -- -- Product candidate to be used for civilian and military vascular trauma repair, the HAV’s lead investigational indication -- DURHAM, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc....
DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2022, on Friday,...
--Seasoned physician, scientist and life science executive brings expertise in clinical research and development across product life cycle-- --Key appointment as Humacyte advances HAV through multiple late-stage clinical trials in initial vascular applications-- DURHAM, N.C., April 05, 2022 (GLOBE...
